Long-term clinical results of biodegradable vascular scaffold ABSORB BVS™ using the PSP-technique in patients with acute coronary syndrome

Hiczkiewicz, Jarosław; Iwańczyk, Sylwia; Araszkiewicz, Aleksander; Łanocha, Magdalena; Hiczkiewicz, Dariusz; Grajek, Stefan; Lesiak, Maciej

doi:10.5603/cj.a2019.0018

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[48][49][50][51] Despite no statistically significant difference in terms of study endpoints occur noticeable unfavorable trend in restenosis ratio in DM t.2 subpopulations occurred (8.1% vs 3.3%; p = 0.182). Additionally taking into consideration unfavorable long-term outcomes of first-generation BRS (Absorb) 41,52 future long-term high-number studies are required for a proper evaluation of Magmaris performance in the diabetic population. Even the ratio of target lesion failure achieved by Magmaris BRS in our study cohort was comparable to the second generation of DES.…”

Section: Discussionmentioning

confidence: 99%

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds – magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Włodarczak

Rola

Barycki

et al. 2023

Diabetes and Vascular Disease Research

Self Cite

View full text Add to dashboard Cite

Background Diabetes type 2 is one of the strongest risk factors affecting coronary artery disease (CAD) and is also a marker of poor short and long-term prognosis in subjects with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) with subsequent drug-eluting stent (DES) implantation. Chronic local vascular inflammation along with endothelial dysfunction is postulated to be the pathophysiological background of unfavorable results. The second generation of metallic magnesium BRS –Magmaris (Biotronik, Berlin, Germany) had been introduced to clinical practice to overcome these limitations. Methods We evaluated 2-years clinical outcomes after Magmaris BRS implantation in NSTE-ACS diabetic ( n-72) and non-diabetic ( n-121) cohorts. Results No significant differences between diabetic and non-diabetes cohorts were noticed in terms of Primary Outcome (cardiac death, myocardial infarction, stent thrombosis) (8.1% vs 3.3% p = 0.182) and Principal secondary outcome – TLF- target lesion failure (9.5% vs 3.3% p = 0.106) at 2-years follow-up. Conclusions 2-years outcome suggests good safety and efficacy of the magnesium BRS (Magmaris) in NSTE- ACS and concomitant DM. Nevertheless, there is a strong need for large multicenter, randomized, prospective studies for a full assessment of this novel device in diabetic patients with ACS.

show abstract

Section: Discussionmentioning

confidence: 99%

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds – magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Włodarczak

Rola

Barycki

et al. 2023

Diabetes and Vascular Disease Research

Self Cite

View full text Add to dashboard Cite

show abstract

Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold

Siu

et al. 2021

Cardiovasc Interv and Ther

View full text Add to dashboard Cite

Unravelling the progress and potential of drug-eluting stents and drug-coated balloons in cardiological insurgencies

Mukheja,

Sarkar,

Arora

et al. 2024

Life Sciences

View full text Add to dashboard Cite

Long-term clinical results of biodegradable vascular scaffold ABSORB BVS™ using the PSP-technique in patients with acute coronary syndrome

Abstract: This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.

Cited by 3 publications

References 27 publications

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds – magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds – magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort

Factors associated with long-term major adverse cardiac events of coronary bioresorbable vascular scaffold

Unravelling the progress and potential of drug-eluting stents and drug-coated balloons in cardiological insurgencies

Contact Info

Product

Resources

About